• Teva will discontinue its Phase 2 TOPAS-MSA trial of emrusolmin in adults with multiple system atrophy.
• Interim findings indicated a low probability of meeting the primary efficacy goal; no safety concerns emerged.
• The interim assessment was not a final efficacy analysis; comprehensive findings will be shared with the scientific community following further analysis.
• A review will include available open-label extension data; the broader emrusolmin program, partnered with MODAG, remains without a final decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800OMX_____CNEWS_EN_GNW1001301263_en) on November 02, 2026, and is solely responsible for the information contained therein.